JPRN-UMIN000004420
Completed
未知
Positron emission tomography (PET) guided therapy of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with or without high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT) - JSCT-NHL10
Japan Study Group for Cell Therapy and Transplantation0 sites68 target enrollmentOctober 20, 2010
ConditionsDiffuse large B-cell lymphoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diffuse large B-cell lymphoma
- Sponsor
- Japan Study Group for Cell Therapy and Transplantation
- Enrollment
- 68
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Patients with a history of prior or concurrent malignancies. 2\.Patients who are on any medication for diabetes. 3\.Patients who have severe complications such as active systematic infection, heart failure, respiratory failure, pulmonary disease, hepatic failure, liver cirrhosis, acute or chronic hepatitis, renal failure, active tuberculosis. 4\.Patients with a history of angina or cardiac infarction. Patients with cardiomyopathy. Patients taking anti\-arrhythmic drugs. 5\.Patients with a history of drug anaphylaxis. 6\.Patients with severe mental illness. 7\.Patients with a history of lymphoma, leukemia, or MDS. 8\.Patients with a history of chemotherapy, cytokine therapy, or antibody therapy for present DLBCL. 9\.Patients with primary central nervous system lymphoma or with central nervous system involvement of DLBCL 10\.Pregnancy or lactation. 11\.Known hepatitis B or C virus infection 12\.Known HIV or HTLV\-1 infection 13\.Patients with any medical condition that in the opinion of the investigator would compromise treatment delivery.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A PET (positron emission tomography) clinical research study using prostate specific membrane antigen (PSMA) targeted tracer, 89Zr-Df-IAB2MProstate cancer / Urothelial carcinoma / Renal cell carcinoma / Testicular cancerJPRN-UMIN000015356niversity of Tsukuba15
Recruiting
Phase 2
Brentuximab Vedotin in combination with donor lymphocyte infusions for Hodgkin lymphoma relapsing or persisting after allogeneic stem cell transplantatioACTRN12619000581167Melbourne Health10
Completed
Not Applicable
Clinical study using positron emission tomography(PET)brain tumor,epilepsy,multiple sclerosis, neuromyelitis,Duchenne musclar dystrophy,Alzheimer's disease,Down Syndrome,HydrocephalusJPRN-UMIN000005626Center for Integrated Human Brain Science, Brain Research Institute, University of Niigata100
Active, not recruiting
Phase 1
PET in aggressive lymphomaAggressive non-Hodgkin's lymphomas (first line therapy)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2006-001641-33-DEniversitätsklinikum Essen696
Active, not recruiting
Phase 1
Positron emission tomography (PET) of patients with brain injury and athletes with concussion symptoms - Descriptive study of the tau tracer 18F-RO6958948Traumatic brain injury (TBI), cerebral haemorrhage (ICH), subarachnoid haemorrhage (SAH) and cerebral commotio.MedDRA version: 21.1Level: PTClassification code 10070976Term: Craniocerebral injurySystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 20.1Level: LLTClassification code 10042320Term: Subarachnoid hemorrhageSystem Organ Class: 100000004852MedDRA version: 20.1Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 21.1Level: LLTClassification code 10022754Term: Intracerebral hemorrhageSystem Organ Class: 100000004852Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2020-002433-15-SERegion Skåne80